Mary Elizabeth Hartnett

Mary Elizabeth Hartnett, MD

Languages spoken: English

Academic Information

Departments Adjunct - Pediatrics , Adjunct - Ophthalmology & Visual Sciences

Board Certification

  • American Board of Ophthalmology

Mary Elizabeth Hartnett, MD, holds the Calvin S. and JeNeal N. Hatch Presidential Endowed Chair in Ophthalmology and Visual Sciences and is a Distinguished Professor at the University of Utah. She is an adjunct professor at the University of Utah departments of Neurobiology and Pediatrics. Dr. Hartnett is the founder and director of Pediatric Retina at the John A. Moran Eye Center and principal investigator of the Retinal Angiogenesis Laboratory.

As director of Moran's Pediatric Retina Center, Dr. Hartnett is one of a few pediatric retina specialists internationally trained to diagnose and treat pediatric retina disorders, which disrupt the healthy development of the light-sensitive tissue at the back of the eye. She also practices as a vitreoretinal surgeon, providing treatment to patients throughout the Mountain West. She performs surgery at the Moran Eye Center and Primary Children's Hospital.

Her mission is to deliver the best possible care and education while conducting critical research to make future advances in pediatric retina care.

She created the first-ever academic textbook on the subject, Pediatric Retina, in its third edition, which has proven to be an invaluable resource for residents and ophthalmologists internationally. She is a co-director of the Advances in Pediatric Retina meeting held every two years, most recently in 2019 at the U.

Dr. Hartnett has received numerous awards, including the Weisenfeld Award, the highest award for clinician-scientists given by the Association for Research in Vision and Ophthalmology (ARVO), in 2018. She received the 2019 Paul Kayser/Retina Research Foundation Global Award, the Macula Society’s 2016 Paul Henkind Award and its 2019 Arnall Patz Medal, and the 2021 Suzanne Veronneau-Troutman Award, the most prestigious award from Women in Ophthalmology. In 2022, she will receive the Gertrude Pyron award, the highest award from the American Association of Retina Specialists. She was one of six at the University of Utah to receive a distinguished research award, for Pediatrics and Ophthalmology.

Dr. Hartnett's prolific publication record includes more than 225 articles in peer-reviewed journals and over 40 book chapters. She has delivered numerous national and international invited lectures. Her long list of professional committee work includes serving as chair of the Publications Committee of ARVO, as a mentor for the ARVO Leadership Development Program, and in leadership positions internationally as chair of the research advisory committees for The Macula Society and the Jack McGovern Coats Disease Foundation as well as Chair of the Credentialing Committee for The Retina Society. She reviews manuscripts for more than 20 eye and science journals and serves on the editorial boards of PlosOne, Molecular Vision, and the American Journal of Ophthalmology. Dr. Hartnett is a Fellow of the American College of Surgeons (FACS) and a Silver and Gold Fellow of the Association for Research in Vision and Ophthalmology (FARVO).

Education History

Undergraduate Rensselaer Polytechnic Institute
 BS
Professional Medical Albany Medical College
 MD
Other Training St. Peter's Hospital
Internship University Hospitals of Cleveland
 Intern
Residency University Hospitals of Cleveland, VA Medical Center
 Resident
Research Fellow Schepens Eye Research Institute, Harvard Medical School
 Research Fellow
Fellowship Massachusetts Eye and Ear Infirmary, Harvard Medical School, Schepens Retina Associates
 Fellow
Fellowship Schepens Retina Associates
 Chief Fellow
Research Fellow Harvard University
 Research Fellow
Fellowship Schepens Retina Associates, Massachusetts Eye and Ear Infirmary, Harvard Medical School
 Fellow
Post Graduate Training Children¿s Hospital and Schepens Eye Research Institute, Harvard University
 Postgraduate Studies

Selected Publications

Journal Article

  1. Lazarus HM, Hartnett ME, Reed MD, Murphy BF, Lass JH (1987). Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis. Am J Ophthalmol, 104(5), 476-80. (Read full article)
  2. Krohel GB, Tobin DR, Hartnett ME, Barrows NA (1982). Divergence paralysis. Am J Ophthalmol, 94(4), 506-10. (Read full article)
  3. Hartnett ME, Katsumi O, Hirose T, Richardson TM, Walton DS (1994). Improved visual function in retinopathy of prematurity after lowering high intraocular pressure. Am J Ophthalmol, 117(1), 113-5. (Read full article)
  4. Hartnett ME, Pruett RC, DaSilva KC, Burkart PT (1994). Antiphospholipid antibody syndrome associated with microscotomata. Am J Ophthalmol, 118(3), 397-8. (Read full article)
  5. Hartnett ME, Coles WH (1993). Lens clarity after vitrectomy in traumatic lens perforation and vitreous penetration. Am J Ophthalmol, 116(2), 250-1. (Read full article)
  6. Hartnett ME, Laposata M, Van Cott E (2003). Antiphospholipid antibody syndrome in a six-year-old female patient. Am J Ophthalmol, 135(4), 542-4. (Read full article)
  7. Bhavsar AR, Ip MS, Glassman AR (2007). The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol, 144(3), 454-6. (Read full article)
  8. Vinekar A, Trese MT, Capone A Jr (2008). Evolution of retinal detachment in posterior retinopathy of prematurity: impact on treatment approach. Am J Ophthalmol, 145(3), 548-555. (Read full article)
  9. Bressler NM, Edwards AR, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Danis RP, Elman MJ, Friedman SM, Glassman AR, Gross JG, Li HK, Murtha TJ, Stone TW, Sun JK (2008). Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol, 145(5), 894-901. (Read full article)
  10. Hartnett ME, Tinkham N, Paynter L, Geisen P, Rosenberg P, Koch G, Cohen KL (2009). Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus. Am J Ophthalmol, 148(6), 895-901.e1. (Read full article)
  11. Hartnett M (2020). Retinopathy of Prematurity: Evolving Treatment With Anti-Vascular Endothelial Growth Factor. American journal of ophthalmology, 218, 208-213. (Read full article)
  12. Ulmasov B, Bruno J, Gordon N, Hartnett ME, Edwards J (2009). Chloride intracellular channel protein-4 functions in angiogenesis by supporting acidification of vacuoles along the intracellular tubulogenic pathway. The American journal of pathology, 174(3), 1084-96. (Read full article)
  13. Bretz CA, Simmons AB, Kunz E, Ramshekar A, Kennedy C, Cardenas I, Hartnett M (2020). Erythropoietin Receptor Signaling Supports Retinal Function after Vascular Injury. The American journal of pathology, 190(3), 630-641. (Read full article)
  14. Hartnett ME, Rodier DW, McColm JR, Thompson H (2003). Long-term vision results measured with Teller Acuity Cards and a new Light Perception/Projection Scale after management of late stages of retinopathy of prematurity. Archives of ophthalmology (Chicago, Ill., 121(7), 991-6. (Read full article)
  15. Hartnett ME, Key IJ, Loyacano NM, Horswell RL, Desalvo K (2005). Perceived barriers to diabetic eye care: qualitative study of patients and physicians. Archives of ophthalmology (Chicago, Ill., 123(3), 387-91. (Read full article)
  16. Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, Browning DJ, Elman MJ, Glassman AR, Gross JG, Kollman C, Wells JA 3r (2009). Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Archives of ophthalmology (Chicago, Ill., 127(2), 132-40. (Read full article)
  17. Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman (2009). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of ophthalmology (Chicago, Ill., 127(3), 245-51. (Read full article)
  18. Holbrook JT, Jabs DA, Weinberg DV, Lewis RA, Davis MD, Friedberg D for the Studies of Ocular Complications of AIDS Research Grou (2003). Visual loss in patients with cytomegalovirus retinitis and AIDS before widespread availability of highly active antiretroviral therapy. Archives of ophthalmology (Chicago, Ill., 121(1), 99-107.
  19. Budd SJ, Hartnett M (2010). Increased Angiogenic Compounds during Persistent Avascular Retina in a Model of ROP. Archives of ophthalmology (Chicago, Ill., 128(8), 1014-21.
  20. Diabetic Retinopathy Clinical Research Networ (2007). Comparison of the modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Archives of ophthalmology (Chicago, Ill., 125(4), 469-80.
  21. Diabetic Retinopathy Clinical Research Networ (2006). Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema. Archives of ophthalmology (Chicago, Ill., 124(12), 1701-7.
  22. Jacobson MA, Tan QX, Girling V, Poon C, Van Natta M, Jabs DA, Inokuma M, Maecker HT, Bredt B, and Sinclair E, for the Studies of Ocular Complications of AIDS Research Grou (2008). Poor predictive value of cytomegalovirus (CMV)-Specific T cell assays for the development of CMV retinitis in patients with AIDS. Clinical infectious diseases, 46, 458-466.
  23. Van Cott EM, Laposata M, Hartnett M (2004). Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis. Blood coagulation & fibrinolysis, 15(5), 393-7. (Read full article)
  24. Mangan KF, Hartnett ME, Matis SA, Winkelstein A, Abo (1984). Natural killer cells suppress human erythroid stem cell proliferation in vitro. Blood, 63(2), 260-9. (Read full article)
  25. Zeng G, Taylor SM, McColm JR, Kappas NC, Kearney JB, Williams LH, Hartnett ME, Bautch V (2007). Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation. Blood, 109(4), 1345-52. (Read full article)
  26. Marshall BC, Jacobson MA, Adler SP in collaboration with the Studies of Ocular Complications of AIDS Research Grou (2004). Avidity of antibodies to cytomegalovirus in HIV-seropositive patients with and without CMV retinitis. Viral immunology, 17, 101-108.
  27. Pivodic A, Johansson H, Smith LEH, Hård AL, Löfqvist C, Yoder BA, Hartnett ME, Wu C, Bründer MC, Lagrèze WA, Stahl A, Al-Hawasi A, Larsson E, Lundgren P, Gränse L, Sunnqvist B, Tornqvist K, Wallin A, Holmström G, Albertsson-Wikland K, Nilsson S, Hellström (2021). Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity. The British journal of ophthalmology, 106(11), 1573-1580. (Read full article)
  28. Zayed MA, Yuan W, Leisner TM, Chalothorn D, McFadden AW, Schaller MD, Hartnett ME, Faber JE, Parise L (2007). CIB1 regulates endothelial cells and ischemia-induced pathological and adaptive angiogenesis. Circulation research, 101(11), 1185-93. (Read full article)
  29. Geisen P, McColm JR, King BM, Hartnett M (2006). Characterization of barrier properties and inducible VEGF expression of several types of retinal pigment epithelium in medium-term culture. Current eye research, 31(9), 739-48. (Read full article)
  30. Hartnett ME, Stratton RD, Browne RW, Rosner BA, Lanham RJ, Armstrong (2000). Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes care, 23(2), 234-40. (Read full article)
  31. Hartnett ME, Lappas A, Darland D, McColm JR, Lovejoy S, D'Amore P (2003). Retinal pigment epithelium and endothelial cell interaction causes retinal pigment epithelial barrier dysfunction via a soluble VEGF-dependent mechanism. Experimental eye research, 77(5), 593-9. (Read full article)
  32. Geisen P, McColm JR, Hartnett M (2006). Choroidal endothelial cells transmigrate across the retinal pigment epithelium but do not proliferate in response to soluble vascular endothelial growth factor. Experimental eye research, 82(4), 608-19. (Read full article)
  33. McColm JR, Geisen P, Peterson LJ, Hartnett M (2006). Exogenous leukemia inhibitory factor (LIF) attenuates retinal vascularization reducing cell proliferation not apoptosis. Experimental eye research, 83(2), 438-46. (Read full article)
  34. Peterson LJ, Wittchen ES, Geisen P, Burridge K, Hartnett M (2007). Heterotypic RPE-choroidal endothelial cell contact increases choroidal endothelial cell transmigration via PI 3-kinase and Rac1. Experimental eye research, 84(4), 737-44. (Read full article)
  35. Budd S, Byfield G, Martiniuk D, Geisen P, Hartnett M (2009). Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP. Experimental eye research, 89(5), 718-27. (Read full article)
  36. Sleath B, Blalock SJ, Robin A, Hartnett ME, Covert D, DeVellis B, Giangiacomo (2010). Development of an instrument to measure glaucoma medication self-efficacy and outcome expectations. Eye (London, England), 24(4), 624-31. (Read full article)
  37. Ramshekar A, Wang H, Kunz E, Pappas C, Hageman GS, Chaqour B, Sacks DB, Hartnett M (2021). Active Rap1-mediated inhibition of choroidal neovascularization requires interactions with IQGAP1 in choroidal endothelial cells. FASEB journal, 35(7), e21642. (Read full article)
  38. Hartnett ME, Hirose T, Richardson TM, Garsd A, Gilbert MM, Krug J J (1992). Intraocular pressure determination in infants with severe retinopathy of prematurity. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 230(5), 406-10. (Read full article)
  39. Hartnett ME, Weiter JJ, Garsd A, Jalkh A (1992). Classification of retinal pigment epithelial detachments associated with drusen. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 230(1), 11-9. (Read full article)
  40. Hartnett ME, Gilbert MM, Hirose T, Richardson TM, Katsumi (1993). Glaucoma as a cause of poor vision in severe retinopathy of prematurity. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 231(8), 433-8. (Read full article)
  41. Remky A, Beausencourt E, Hartnett ME, Trempe CL, Arend O, Elsner A (1999). Infrared imaging of cystoid macular edema. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 237(11), 897-901. (Read full article)
  42. Mangalesh S, Bleicher ID, Chen X, Viehland C, LaRocca F, Izatt JA, Freedman SF, Hartnett ME, Toth C (2019). Three-dimensional pattern of extraretinal neovascular development in retinopathy of prematurity. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 257(4), 677-688. (Read full article)
  43. Steidl S, Hirose T, Hartnett M (1995). Open-sky vitrectomy for posterior segment reconstruction in eyes with severe trauma. International ophthalmology clinics, 35(1), 175-80. (Read full article)
  44. Sheindlin JA, Hirose T, Hartnett M (1999). Ophthalmic endoscopy: applications in intraocular surgery. International ophthalmology clinics, 39(1), 237-47. (Read full article)
  45. Andrews AP, Hartnett ME, Hirose (1999). Surgical advances in retinopathy of prematurity. International ophthalmology clinics, 39(1), 275-90. (Read full article)
  46. Hartnett ME, Garcia CM, D'Amore P (1999). Release of bFGF, an endothelial cell survival factor, by osmotic shock. Investigative ophthalmology & visual science, 40(12), 2945-51. (Read full article)
  47. Hartnett ME, Martiniuk DJ, Saito Y, Geisen P, Peterson LJ, McColm J (2006). Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy. Investigative ophthalmology & visual science, 47(11), 4975-82. (Read full article)
  48. Davis MD, Bressler SB, Aiello LP, Bressler NM, Browning DJ, Flaxel CJ, Fong DS, Foster WJ, Glassman AR, Hartnett ME, Kollman C, Li HK, Qin H, Scott I (2008). Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema. Investigative ophthalmology & visual science, 49(5), 1745-52. (Read full article)
  49. Hartnett ME, Martiniuk D, Byfield G, Geisen P, Zeng G, Bautch V (2008). Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease. Investigative ophthalmology & visual science, 49(7), 3107-14. (Read full article)
  50. Saito Y, Uppal A, Byfield G, Budd S, Hartnett M (2008). Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model. Investigative ophthalmology & visual science, 49(4), 1591-8. (Read full article)
  51. Byfield G, Budd S, Hartnett M (2009). The role of supplemental oxygen and JAK/STAT signaling in intravitreous neovascularization in a ROP rat model. Investigative ophthalmology & visual science, 50(7), 3360-5. (Read full article)
  52. Zayed MA, Uppal A, Hartnett M (2010). New-onset maternal gestational hypertension and risk of retinopathy of prematurity. Investigative ophthalmology & visual science, 51(10), 4983-8. (Read full article)
  53. Reynolds R, Hartnett ME, Rosner B, Atkinson J, Giclas PC, Seddon J (2009). Plasma Complement Components and Activation Fragments are Associated with Age-Related Macular Degeneration Genotypes and Phenotypes. Investigative ophthalmology & visual science,
  54. Mastey RR, Georgiou M, Langlo CS, Kalitzeos A, Patterson EJ, Kane T, Singh N, Vincent A, Moore AT, Tsang SH, Lin JH, Young MP, Hartnett ME, Héon E, Kohl S, Michaelides M, Carroll (2019). Characterization of Retinal Structure in ATF6-Associated Achromatopsia. Investigative ophthalmology & visual science, 60(7), 2631-2640. (Read full article)
  55. Han X, Kong J, Hartnett ME, Wang (2019). Enhancing Retinal Endothelial Glycolysis by Inhibiting UCP2 Promotes Physiologic Retinal Vascular Development in a Model of Retinopathy of Prematurity. Investigative ophthalmology & visual science, 60(5), 1604-1613. (Read full article)
  56. Hartnett M (2019). Discovering Mechanisms in the Changing and Diverse Pathology of Retinopathy of Prematurity: The Weisenfeld Award Lecture. Investigative ophthalmology & visual science, 60(5), 1286-1297. (Read full article)
  57. Bretz CA, Ramshekar A, Kunz E, Wang H, Hartnett M (2020). Signaling Through the Erythropoietin Receptor Affects Angiogenesis in Retinovascular Disease. Investigative ophthalmology & visual science, 61(10), 23. (Read full article)
  58. Yarishkin O, Phuong TTT, Bretz CA, Olsen KW, Baumann JM, Lakk M, Crandall A, Heurteaux C, Hartnett ME, Kri'aj (2018). TREK-1 channels regulate pressure sensitivity and calcium signaling in trabecular meshwork cells. The Journal of general physiology, 150(12), 1660-1675. (Read full article)
  59. Jacobson MA, Maecker HT, Orr PL, D'Amico R, Van Natta M, Li XD Pollard RB, Bredt BM for the Adult AIDS Clinical Trials Group and the Studies of Ocular Complications of AIDS Research Grou (2004). Results of a CMV-specific CD8+/IFNy+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in AIDS patients with CMV retinitis. The Journal of infectious diseases, 189, 1362-1373.
  60. Thornburg CD, Erickson SW, Page GP, Clark EAS, DeAngelis MM, Hartnett ME, Goldstein RF, Dagle JM, Murray JC, Poindexter BB, Das A, Cotten C (2020). Correction: Genetic predictors of severe intraventricular hemorrhage in extremely low-birthweight infants. Journal of perinatology,
  61. Escaravage GK Jr, Cohen KL, Patel SB, Hartnett ME, Armstrong BD, Janowski C (2006). Quantification of macular and optic disc hyperfluorescence after phacoemulsification in diabetes mellitus. Journal of cataract and refractive surgery, 32(5), 803-11. (Read full article)
  62. Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K, Kaneko H, Albuquerque RJ, Dridi S, Saito K, Raisler BJ, Budd SJ, Geisen P, Munitz A, Ambati BK, Green MG, Ishibashi T, Wright JD, Humbles AA, Gerard CJ, Ogura Y, Pan Y, Smith JR, Grisanti S, Hartnett ME, Rothenberg ME, Ambati (2009). CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature, 460(7252), 225-30. (Read full article)
  63. Hartnett ME, Gilbert MM, Richardson TM, Krug JH Jr, Hirose (1990). Anterior segment evaluation of infants with retinopathy of prematurity. Ophthalmology, 97(1), 122-30. (Read full article)
  64. Hartnett ME, Elsner A (1996). Characteristics of exudative age-related macular degeneration determined in vivo with confocal and indirect infrared imaging. Ophthalmology, 103(1), 58-71. (Read full article)
  65. Hartnett ME, Weiter JJ, Staurenghi G, Elsner A (1996). Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. Ophthalmology, 103(12), 2042-53. (Read full article)
  66. Beausencourt E, Elsner AE, Hartnett ME, Trempe C (1997). Quantitative analysis of macular holes with scanning laser tomography. Ophthalmology, 104(12), 2018-29. (Read full article)
  67. Kunze C, Elsner AE, Beausencourt E, Moraes L, Hartnett ME, Trempe C (1999). Spatial extent of pigment epithelial detachments in age-related macular degeneration. Ophthalmology, 106(9), 1830-40. (Read full article)
  68. Beausencourt E, Remky A, Elsner AE, Hartnett ME, Trempe C (2000). Infrared scanning laser tomography of macular cysts. Ophthalmology, 107(2), 375-85. (Read full article)
  69. Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin (2008). Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology, 115(8), 1366-71, 1371.e1. (Read full article)
  70. Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Jumper JM, Figueroa (2009). SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. Ophthalmology, 116(3), 504-12. (Read full article)
  71. Scott IU, Blodi BA, Ip MS, Vanveldhuisen PC, Oden NL, Chan CK, Gonzalez (2009). SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type. Ophthalmology, 116(4), 756-61. (Read full article)
  72. Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD, for the Studies of Ocular Complications of AIDS Research Grou (2007). Longitudinal Study of the Ocular Complications of AIDS. 2. Ocular examination results at enrollment. Ophthalmology, 114, 787-793.
  73. Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD, for the Studies of Ocular Complications of AIDS Research Grou (2007). Longitudinal Study of the Ocular Complications of AIDS. 1. Ocular diagnoses at enrollment. Ophthalmology, 114, 780-786.
  74. PKC-DRS2 Group (PI for LSU site (2006). Effect of Ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology, 113, 2221-2230.
  75. Kempen JH, Min Y-I, Freeman WR, Holland GN, Friedberg DN, Dieterich DT, Jabs DA for the Studies of Ocular Complications of AIDS Research Grou (2006). Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology, 113, 684-694.
  76. Thorne JE, Jabs DA, Kempen JH, Holbrook JT, Nichols C, Meinert CL, for the Studies of Ocular Complications of AIDS Research Grou (2006). Causes of Visual Acuity Loss Among Patients with AIDS and Cytomegalovirus in the Era of Highly Active Antiretroviral Therapy. Ophthalmology, 113, 1441-1445.
  77. Jabs DA, Van Natta ML, Thorne JE, Weinberg DV, Meredith TA, Kuppermann BD, Sepkowitz K, Li HK for the Studies of Ocular Complications of AIDS Research Grou (2004). Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology, 111, 2232-2239.
  78. Kempen JH, Martin BK, Wu A, Barron B, Thorne JE, Jabs DA for the Studies of Ocular Complications of AIDS Research Grou (2003). The effect of cytomegalovirus retinitis on the quality of life of patients with acquired immune deficiency syndrome in the era of highly active anti-retroviral therapy. Ophthalmology, 110, 987-995.
  79. Diabetic Retinopathy Clinical Research Networ (2008). A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology, 115, 1445-1456.
  80. Steering Committee of Diabetic Retinopathy Clinical Research Networ (2007). A phase 2 randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology, 114, 1860-1867.
  81. Diabetic Retinopathy Clinical Research Networ (2007). Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology, 114(8), 1520-5.
  82. Diabetic Retinopathy Clinical Research Networ (2007). Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology, 114(3), 525-36.
  83. Steidl SM, Hirose T, Sang D, Hartnett M (1996). Difficulties in excluding the diagnosis of retinoblastoma in cases of advanced Coats' disease: a clinicopathologic report. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 210(6), 336-40. (Read full article)
  84. The STOP-ROP Multicenter Study Grou (2000). Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), A randomized, controlled trial. I: Primary Outcomes. Pediatrics, 105, 295-310.
  85. Hartnett ME, Hirose (1998). Cyanoacrylate glue in the repair of retinal detachment associated with posterior retinal breaks in infants and children. Retina (Philadelphia, Pa.), 18(2), 125-9. (Read full article)
  86. Miura M, Elsner AE, Beausencourt E, Kunze C, Hartnett ME, Lashkari K, Trempe C (2002). Grading of infrared confocal scanning laser tomography and video displays of digitized color slides in exudative age-related macular degeneration. Retina (Philadelphia, Pa.), 22(3), 300-8. (Read full article)
  87. Hartnett M (2003). Features associated with surgical outcome in patients with stages 4 and 5 retinopathy of prematurity. Retina (Philadelphia, Pa.), 23(3), 322-9. (Read full article)
  88. Hartnett ME, McColm J (2004). Retinal features predictive of progressive stage 4 retinopathy of prematurity. Retina (Philadelphia, Pa.), 24(2), 237-41. (Read full article)
  89. Hartnett ME, Maguluri S, Thompson HW, McColm J (2004). Comparison of retinal outcomes after scleral buckle or lens-sparing vitrectomy for stage 4 retinopathy of prematurity. Retina (Philadelphia, Pa.), 24(5), 753-7. (Read full article)
  90. Hartnett ME, McColm J (2006). Fibrovascular organization in the vitreous following laser for ROP: implications for prognosis. Retina (Philadelphia, Pa.), 26(7 Suppl), S24-31. (Read full article)
  91. Balasubramanian M, Capone A Jr, Hartnett ME, Pignatto S, Trese M (2006). The Photographic Screening for Retinopathy of Prematurity Study (Photo-ROP): study design and baseline characteristics of enrolled patients. Retina (Philadelphia, Pa.), 26(7 Suppl), S4-10. (Read full article)
  92. Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, Davis MD, Kollman C, Qin (2008). Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. Retina (Philadelphia, Pa.), 28(1), 36-40. (Read full article)
  93. Hartnett ME, Board RJ, Houghton (2008). Subretinal hemorrhage after lens-sparing vitrectomy in infants born at or under 24 weeks gestation. Retina (Philadelphia, Pa.), 28(3 Suppl), S69-74. (Read full article)
  94. Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin (2008). A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina (Philadelphia, Pa.), 28(7), 919-30. (Read full article)
  95. Writing Committee for The Photographic Screening for Retinopathy of Prematurity Study (Photo- ROP (2008). Primary Outcomes Ophthalmology. Retina (Philadelphia, Pa.), 28, S47-S54.
  96. Maguluri S, Hartnett M (2003). Radial choroidal ruptures in sclopetaria. Journal of the American College of Surgeons, 197(4), 689-90. (Read full article)
  97. McColm JR, Geisen P, Hartnett M (2004). VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Molecular vision, 10, 512-20. (Read full article)
  98. Saito Y, Geisen P, Uppal A, Hartnett M (2007). Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity. Molecular vision, 13, 840-53. (Read full article)
  99. Geisen P, Peterson LJ, Martiniuk D, Uppal A, Saito Y, Hartnett M (2008). Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity. Molecular vision, 14, 345-57. (Read full article)
  100. Simmons MA, Cheng AV, Becker S, Gerkin RD, Hartnett M (2018). Automatic analysis of the retinal avascular area in the rat oxygen-induced retinopathy model. Molecular vision, 24, 767-777. (Read full article)
  101. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett M (2008). Vascular endothelial growth factor in eye disease. Progress in retinal and eye research, 27(4), 331-71. (Read full article)
  102. Spaide RF, Gemmy Cheung CM, Matsumoto H, Kishi S, Boon CJF, van Dijk EHC, Mauget-Faysse M, Behar-Cohen F, Hartnett ME, Sivaprasad S, Iida T, Brown DM, Chhablani J, Maloca P (2021). Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders. Progress in retinal and eye research, 100973. (Read full article)
  103. Armstrong D, Ueda T, Ueda T, Aljada A, Browne R, Fukuda S, Spengler R, Chou R, Hartnett M, Buch P, Dandona P, Sasisekharan R, Dorey C (1998). Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-alpha, vascular endothelial growth factor and platelet-derived growth factor. Angiogenesis, 2(1), 93-104. (Read full article)
  104. Armstrong D, Ueda To, Ueda Ta, Browne R, Al-Jada A, Spengler R, Chou R, Fukuda S, Buch P, Dandona P, Hartnett ME, Sasisekharan R, Dorey K (1997). Expression of TNF-alpha and VEGF during retinal neovascularization is initiated by lipid hydroperoxide. Angiogenesis, 2, 174-84.
  105. Wang H, Ramshekar A, Kunz E, Hartnett M (2021). 7-ketocholesterol induces endothelial-mesenchymal transition and promotes fibrosis: implications in neovascular age-related macular degeneration and treatment. Angiogenesis, 24(3), 583-595. (Read full article)
  106. Hansen ED, Hartnett M (2019). A review of treatment for retinopathy of prematurity. Expert review of ophthalmology, 14(2), 73-87. (Read full article)
  107. Wang H, Kunz E, Stoddard GJ, Hauswirth WW, Hartnett M (2019). Optimal Inhibition of Choroidal Neovascularization by scAAV2 with VMD2 Promoter-driven Active Rap1a in the RPE. Scientific reports, 9(1), 15732. (Read full article)
  108. Birch DG, Bernstein PS, Iannacone A, Pennesi ME, Lam BL, Heckenlively J, Csaky K, Hartnett ME, Winthrop KL, Jayasundera T, Hughbanks-Wheaton DK, Warner J, Yang P, Fish GE, Teske MP, Sklaver NL, Erker L, Chegarnov E, Smith T, Wahle A, VanVeldhuisen PC, McCormack J, Lindblad R, Bramer S, Rose S, Zilliox P, Francis PJ, Weleber R (2018). Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial. JAMA ophthalmology, 136(8), 849-856. (Read full article)
  109. Greene T, Hartnett M (2019). Programming Error Led to Underestimate of Effect Sizes in Study of Association of Maternal Preeclampsia and Risk of Infant Retinopathy of Prematurity. JAMA ophthalmology, 137(1), 119. (Read full article)
  110. Jeng-Miller KW, Soomro T, Scott NL, Rao P, Marlow E, Chang EY, Ells A, Chau F, Nudleman E, Calvo CM, Patel N, Schwartz R, Cernichiaro-Espinosa LA, Montoya AG, Goldstein J, Harper CA 3rd, Baumal CR, Hartnett ME, Harbour JW, Besirli CG, Gupta MP, Chan RVP, Drenser KA, Capone A Jr, Murray TG, Mukai S, Trese MT, Berrocal AM, Wong SC, Yonekawa (2019). Longitudinal Examination of Fellow-Eye Vascular Anomalies in Coats' Disease With Widefield Fluorescein Angiography: A Multicenter Study. Ophthalmic surgery, lasers & imaging retina, 50(4), 221-227. (Read full article)
  111. Hartnett ME, Toth C (2019). Experimental Evidence Behind Clinical Trial Outcomes in Retinopathy of Prematurity. Ophthalmic surgery, lasers & imaging retina, 50(4), 228-234. (Read full article)
  112. Shulman JP, Hartnett M (2018). Corrigendum: Pharmacotherapy and ROP: Going Back to the Basics. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 7(5), 365. (Read full article)
  113. Hicks PM, Haaland B, Feehan M, Crandall AS, Pettey JH, Nuttall E, Self W, Hartnett ME, Bernstein P, Vitale A, Shakoor A, Shulman JP, Sieminski SF, Kim I, Owen LA, Murtaugh MA, Noyes A, DeAngelis M (2020). Systemic Disease and Ocular Comorbidity Analysis of Geographically Isolated Federally Recognized American Indian Tribes of the Intermountain West. Journal of clinical medicine, 9(11), (Read full article)
  114. Global Retinoblastoma Study Group., Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Adamou Boubacar S, Ademola-Popoola DS, Adio A, Afshar AR, Aggarwal P, Aghaji AE, Ahmad A, Akib MNR, Al Harby L, Al Ani MH, Alakbarova A, Portabella SA, Al-Badri SAF, Alcasabas APA, Al-Dahmash SA, Alejos A, Alemany-Rubio E, Alfa Bio AI, Alfonso Carreras Y, Al-Haddad C, Al-Hussaini HHY, Ali AM, Alia DB, Al-Jadiry MF, Al-Jumaily U, Alkatan HM, All-Eriksson C, Al-Mafrachi AARM, Almeida AA, Alsawidi KM, Al-Shaheen AASM, Al-Shammary EH, Amiruddin PO, Antonino R, Astbury NJ, Atalay HT, Atchaneeyasakul LO, Atsiaya R, Attaseth T, Aung TH, Ayala S, Baizakova B, Balaguer J, Balayeva R, Balwierz W, Barranco H, Bascaran C, Beck Popovic M, Benavides R, Benmiloud S, Bennani Guebessi N, Berete RC, Berry JL, Bhaduri A, Bhat S, Biddulph SJ, Biewald EM, Bobrova N, Boehme M, Boldt HC, Bonanomi MTBC, Bornfeld N, Bouda GC, Bouguila H, Boumedane A, Brennan RC, Brichard BG, Buaboonnam J, Calderón-Sotelo P, Calle Jara DA, Camuglia JE, Cano MR, Capra M, Cassoux N, Castela G, Castillo L, Català-Mora J, Chantada GL, Chaudhry S, Chaugule SS, Chauhan A, Chawla B, Chernodrinska VS, Chiwanga FS, Chuluunbat T, Cieslik K, Cockcroft RL, Comsa C, Correa ZM, Correa Llano MG, Corson TW, Cowan-Lyn KE, Csóka M, Cui X, Da Gama IV, Dangboon W, Das A, Das S, Davanzo JM, Davidson A, De Potter P, Delgado KQ, Demirci H, Desjardins L, Diaz Coronado RY, Dimaras H, Dodgshun AJ, Donaldson C, Donato Macedo CR, Dragomir MD, Du Y, Du Bruyn M, Edison KS, Eka Sutyawan IW, El Kettani A, Elbahi AM, Elder JE, Elgalaly D, Elhaddad AM, Elhassan MMA, Elzembely MM, Essuman VA, Evina TGA, Fadoo Z, Fandiño AC, Faranoush M, Fasina O, Fernández DDPG, Fernández-Teijeiro A, Foster A, Frenkel S, Fu LD, Fuentes-Alabi SL, Gallie BL, Gandiwa M, Garcia JL, García Aldana D, Gassant PY, Geel JA, Ghassemi F, Girón AV, Gizachew Z, Goenz MA, Gold AS, Goldberg-Lavid M, Gole GA, Gomel N, Gonzalez E, Gonzalez Perez G, González-Rodríguez L, Garcia Pacheco HN, Graells J, Green L, Gregersen PA, Grigorovski NDAK, Guedenon KM, Gunasekera DS, Gündüz AK, Gupta H, Gupta S, Hadjistilianou T, Hamel P, Hamid SA, Hamzah N, Hansen ED, Harbour JW, Hartnett ME, Hasanreisoglu M, Hassan S, Hassan S, Hederova S, Hernandez J, Hernandez LMC, Hessissen L, Hordofa DF, Huang LC, Hubbard GB, Hummlen M, Husakova K, Hussein Al-Janabi AN, Ida R, Ilic VR, Jairaj V, Jeeva I, Jenkinson H, Ji X, Jo DH, Johnson KP, Johnson WJ, Jones MM, Kabesha TBA, Kabore RL, Kaliki S, Kalinaki A, Kantar M, Kao LY, Kardava T, Kebudi R, Kepak T, Keren-Froim N, Khan ZJ, Khaqan HA, Khauv P, Kheir WJ, Khetan V, Khodabande A, Khotenashvili Z, Kim JW, Kim JH, Kiratli H, Kivelä TT, Klett A, Komba Palet JEK, Krivaitiene D, Kruger M, Kulvichit K, Kuntorini MW, Kyara A, Lachmann ES, Lam CPS, Lam GC, Larson SA, Latinovic S, Laurenti KD, Le BHA, Lecuona K, Leverant AA, Li C, Limbu B, Long QB, López JP, Lukamba RM, Lumbroso L, Luna-Fineman S, Lutfi D, Lysytsia L, Magrath GN, Mahajan A, Majeed AR, Maka E, Makan M, Makimbetov EK, Manda C, Martín Begue N, Mason L, Mason JO 3rd, Matende IO, Materin M, Mattosinho CCDS, Matua M, Mayet I, Mbumba FB, McKenzie JD, Medina-Sanson A, Mehrvar A, Mengesha AA, Menon V, Mercado GJVD, Mets MB, Midena E, Mishra DKC, Mndeme FG, Mohamedani AA, Mohammad MT, Moll AC, Montero MM, Morales RA, Moreira C, Mruthyunjaya P, Msina MS, Msukwa G, Mudaliar SS, Muma KI, Munier FL, Murgoi G, Murray TG, Musa KO, Mushtaq A, Mustak H, Muyen OM, Naidu G, Nair AG, Naumenko L, Ndoye Roth PA, Nency YM, Neroev V, Ngo H, Nieves RM, Nikitovic M, Nkanga ED, Nkumbe H, Nuruddin M, Nyaywa M, Obono-Obiang G, Oguego NC, Olechowski A, Oliver SCN, Osei-Bonsu P, Ossandon D, Paez-Escamilla MA, Pagarra H, Painter SL, Paintsil V, Paiva L, Pal BP, Palanivelu MS, Papyan R, Parrozzani R, Parulekar M, Pascual Morales CR, Paton KE, Pawinska-Wasikowska K, Pe'er J, Peña A, Peric S, Pham CTM, Philbert R, Plager DA, Pochop P, Polania RA, Polyakov VG, Pompe MT, Pons JJ, Prat D, (2020). Global Retinoblastoma Presentation and Analysis by National Income Level. JAMA oncology, 6(5), 685-695. (Read full article)
  115. Levine ES, Custo Greig E, Mendonça LSM, Gulati S, Despotovic IN, Alibhai AY, Moult E, Muakkassa N, Quaranta-El Maftouhi M, El Maftouhi A, Chakravarthy U, Fujimoto JG, Baumal CR, Witkin AJ, Duker JS, Hartnett ME, Waheed N (2020). The long-term effects of anti-vascular endothelial growth factor therapy on the optical coherence tomography angiographic appearance of neovascularization in age-related macular degeneration. International journal of retina and vitreous, 6, 39. (Read full article)
  116. Hamad AE, Moinuddin O, Blair MP, Schechet SA, Shapiro MJ, Quiram PA, Mammo DA, Berrocal AM, Prakhunhungsit S, Cernichiaro-Espinosa LA, Mukai S, Yonekawa Y, Ung C, Holz ER, Harper CA 3rd, Young RC, Besirli CG, Nagiel A, Lee TC, Gupta MP, Walsh MK, Khawly JA, Campbell JP, Kychenthal A, Nudleman ED, Robinson JE, Hartnett ME, Calvo CM, Chang E (2020). Late-Onset Retinal Findings and Complications in Untreated Retinopathy of Prematurity. Ophthalmology. Retina, 4(6), 602-612. (Read full article)
  117. Stagg BC, Stein JD, Medeiros FA, Wirostko B, Crandall A, Hartnett ME, Cummins M, Morris A, Hess R, Kawamoto (2021). Special Commentary: Using Clinical Decision Support Systems to Bring Predictive Models to the Glaucoma Clinic. Ophthalmology. Glaucoma, 4(1), 5-9. (Read full article)
  118. Hicks PM, Melendez SAC, Vitale A, Self W, Hartnett ME, Bernstein P, Morgan DJ, Feehan M, Shakoor A, Kim I, Owen LA, DeAngelis M (2019). Genetic Epidemiologic Analysis of Hypertensive Retinopathy in an Underrepresented and Rare Federally Recognized Native American Population of the Intermountain West. Journal of community medicine & public health, 3(1), (Read full article)

Edited Book

  1. Steidl S, Hartnett M (2003). Clinical Pathways in Vitreoretinal Disease.
  2. Hartnett ME, ed-in-chie (2005). Pediatric Retina, 1st Edition.
  3. Schepens CL, Hartnett ME, Hirose (2000). Schepens¿ Retinal Detachment and Allied Diseases.